CADTH reimbursement recommendation Hoffmann-La Roche Ltd. : indication: bleeding prevention, hemophilia A (congenital factor VIII deficiency). Emicizumab (Hemlibra)

Ejemplares similares

• CADTH Canadian Drug Expert Committee recommendation : indication : Parkinson's disease. Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.)
  por: Canadian Agency for Drugs and Technologies in Health,
  Publicado: (2018)
• CADTH Canadian Drug Expert Committee recommendation : indication : diabetes mellitus, type 2. Ertugliflozin/Metformin (Segluromet -- Merck Canada Inc.)
  por: Canadian Agency for Drugs and Technologies in Health,
  Publicado: (2019)
• CADTH Canadian Drug Expert Committee recommendation : indication : chronic hepatitis C virus infection. Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.)
  por: Canadian Agency for Drugs and Technologies in Health,
  Publicado: (2018)
• CADTH Canadian Drug Expert Committee recommendation : indication : the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Nitisinone (MDK-Nitisinone - )
  por: Canadian Agency for Drugs and Technologies in Health,
  Publicado: (2018)
• CADTH Canadian drug expert committee recommendation (final) : indication : treatment of adult patients with moderate-to severe plaque psoriasis who are candidates for systemic therapy. Certolizumab pegol (Cimzia -- UCB Canada Inc.)
  por: Canadian Agency for Drugs and Technologies in Health,
  Publicado: (2019)